• Marlon G Saria, Courtney Corle, Jethro Hu, Jeremy D Rudnick, Surasak Phuphanich, Maciej M Mrugala, Laura K Crew, Daniela A Bota, Beverly Dan Fu, Ryan Y Kim, Tiffany Brown, Homira Feely, Joanne Brechlin, Bradley D Brown, Jan Drappatz, Patrick Y Wen, Clark C Chen, Bob Carter, Jong Woo Lee, and Santosh Kesari.
• Department of Neurosciences, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093-0819, USA. skesari@ucsd.edu
• J. Neurosurg.. 2013 Jun 1;118(6):1183-7.

ObjectThe object of this study was to determine the tolerability and activity of lacosamide in patients with brain tumors.MethodsThe authors reviewed the medical records at 5 US academic medical centers with tertiary brain tumor programs, seeking all patients in whom a primary brain tumor had been diagnosed and who were taking lacosamide.ResultsThe authors identified 70 patients with primary brain tumors and reviewed seizure frequency and toxicities. The majority of the patients had gliomas (96%). Fifty-five (78%) had partial seizures only, and 12 (17%) had generalized seizures. Most of the patients (74%) were started on lacosamide because of recurrent seizures. Forty-six patients (66%) reported a decrease in seizure frequency, and 21 patients (30%) reported stable seizures. Most of the patients (54 [77%]) placed on lacosamide did not report any toxicities.ConclusionsThis retrospective analysis demonstrated that lacosamide was both well tolerated and active as an add-on antiepileptic drug (AED) in patients with brain tumors. Lacosamide's novel mechanism of action will allow for concurrent use with other AEDs, as documented by its activity across many different types of AEDs used in this patient population. Larger prospective studies are warranted.

27 keywords...

hide…